Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Fungal Microbiota Dysbiosis Seen in Inflammatory Bowel Disease

Anne Harding  |  February 13, 2016

NEW YORK (Reuters Health)—Patients with inflammatory bowel disease (IBD) show imbalance in their fungal intestinal microbiota, according to new findings. “The fungal microbiota is a new actor to take into account in the pathogenesis of IBD and potentially in other diseases,” Dr. Harry Sokol of Hospital Saint-Antoine in Paris, an author of the new study,…

Tofacitinib Decreases Inflammation in Early RA

Michele B. Kaufman, PharmD, BCGP  |  February 12, 2016

A recent study used MRI to show that tofacitinib reduces inflammation and inhibition of the progression of structural damage in adults with early RA…

Textile Workers at Higher Risk for Rheumatoid Arthritis

Lisa Rapaport  |  February 12, 2016

(Reuters Health)—Breathing textile dust on the job is linked to an almost tripled risk of developing rheumatoid arthritis (RA), a Malaysian study suggests. While smoking is a known risk factor for RA, the findings add to evidence suggesting that environmental factors could trigger RA in some people, the researchers note in their report in Annals…

How Technology Can Benefit Rheumatology Practices

Richard Quinn  |  February 12, 2016

Electronic health records, mobile apps, telemedicine, patient portals—new technologies offer rheumatologists more efficiency and patients greater knowledge. Here are a few ways these technologies can aid a practice…

Gut-on-a-Chip Provides Insight into Microbiome & Intestinal Inflammation

Lara C. Pullen, PhD  |  February 8, 2016

Researchers have created a microdevice with Caco-2 intestinal epithelial cells to aid in studying the human gut microbiome’s role in homeostasis, immune modulation and pathology. Using this gut-on-a-chip, researchers were able to examine in detail the processes they think result in chronic intestinal inflammation…

No Cause Found Yet for Botched French Drug Trial

Reuters Staff  |  February 7, 2016

PARIS (Reuters)—An initial report into a drug trial in northwestern France that left one person dead and five others hospitalized last month did not identify the exact cause, French Health Minister Marisol Touraine said on Thursday. Touraine told a news conference that the condition of the five people who were hospitalized was improving and that…

Bowing to Pressure, FDA to Reform Painkiller Approval Process

Toni Clarke  |  February 7, 2016

WASHINGTON (Reuters)—Bowing to pressure from lawmakers, Dr. Robert Califf, President Barack Obama’s nominee to lead the U.S. Food and Drug Administration (FDA), said on Thursday the agency would reform its process for approving opioid painkillers. Last month, Sen. Edward Markey (D-Ma.) placed a hold on Califf’s nomination, preventing it from being voted on by the…

U.S. Appeals Court: Hospitals Can Be ‘Urban’ & ‘Rural’ at Same Time

Jonathan Stempel  |  February 6, 2016

NEW YORK (Reuters)—The federal appeals court in New York struck down a U.S. regulation that made it harder for hospitals to provide better medical care at lower cost by claiming they were “rural” for some purposes and “urban” for others. Thursday’s decision by the Second U.S. Circuit Court of Appeals is a victory for hospitals…

FDA Advisory Panel Strongly Backs Biosimilar Form of Remicade

Reuters Staff  |  February 6, 2016

(Reuters)—A medical advisory panel to the U.S. Food and Drug Administration on Tuesday recommended approval of a cheaper biosimilar form of Johnson & Johnson’s arthritis drug Remicade (infliximab) that could eventually batter sales of the branded product. The panel, by a vote of 21-3, supported use of the biosimilar from Celltrion Inc. and Pfizer Inc.,…

California Doctor Gets 30 Years to Life in Landmark Overdose Case

Steve Gorman  |  February 6, 2016

LOS ANGELES (Reuters)—A Southern California doctor was sentenced to 30 years to life in prison on Friday for over-prescribing drugs that caused the fatal overdose of three patients in a murder case capped by the first conviction of its kind in the U.S. The case against Dr. Hsiu Ying “Lisa” Tseng, 46, comes amid what…

  • « Previous Page
  • 1
  • …
  • 528
  • 529
  • 530
  • 531
  • 532
  • …
  • 819
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences